HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Different expression of transforming growth factor beta 1 in pancreatic ductal adenocarcinoma and cystic neoplasms.

Abstract
Pancreatic neoplasms harbor different prognoses according to their histological type: a benign course for serous cystadenoma, a low malignant potential for intraductal papillary mucinous neoplasms (IPMN), and high aggressiveness for ductal adenocarcinoma (ADC). Transforming growth factor beta 1 (TGF beta 1) may regulate tumor growth. The present study analyzes and compares the expression of its precursor beta 1-latency-associated peptide (beta 1-LAP), its latent binding protein (LTBP), and its mRNA in ductal adenocarcinoma (n = 10), in IPMN (n = 8), in serous cystadenoma (n = 2), and in normal tissues (n = 5). LTBP is thought to play a strategic role in the processing and active secretion of latent TGF beta 1 and its stockage in the extracellular matrix. Localization of beta 1-LAP and LTBP was assessed by immunohistochemistry using specific antibodies and expression of TGF beta 1 mRNA by reverse-transcriptase polymerase chain reaction analysis. beta 1-LAP was only slightly expressed in normal specimens, while LTBP was not detected. beta 1-LAP was detected in the cytoplasm of neoplastic cells in 9 of 10 patients with ADC. An intense staining was present in stromal cells surrounding the neoplastic glands in all cases except in one carcinoma in situ. LTBP was detected only in stromal cells and in the surrounding extracellular matrix. In IPMN with mild-grade dysplasia and in cystadenoma, beta 1-LAP was strongly expressed in the epithelial cells, while it was poorly detected in invasive IPMN; stromal cells were poorly or not all stained by beta 1-LAP, except in invasive IPMN (n = 2). LTBP was detected in neoplastic cells of three cases with benign IPMN and two of two cases with cystadenoma, while stroma was not immunostained. TGF beta 1 mRNA was strongly expressed in most of the tumors and no difference in expression was observed between the different types of neoplasms. There is no quantitative difference in expression of TGF beta 1 in ADC and in IPMN or cystadenoma. However, the latter are able to secrete TGF beta 1 efficiently, in contrast to ductal ADC as shown by the ability of the neoplastic cells to express both beta 1-LAP and LTBP. Invasive stroma reaction was associated with enhanced beta 1-LAP and LTBP expression in stromal cells and could be mediated by TGF beta 1 via LTBP
AuthorsJ L Van Laethem, A Resibois, F Rickaert, J Devière, M Gelin, M Cremer, P Robberecht
JournalPancreas (Pancreas) Vol. 15 Issue 1 Pg. 41-7 (Jul 1997) ISSN: 0885-3177 [Print] United States
PMID9211491 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Carrier Proteins
  • DNA Primers
  • Intracellular Signaling Peptides and Proteins
  • Latent TGF-beta Binding Proteins
  • Peptide Fragments
  • Protein Precursors
  • Proteins
  • RNA, Messenger
  • RNA, Neoplasm
  • Transforming Growth Factor beta
  • Transforming Growth Factor beta1
Topics
  • Adenocarcinoma, Mucinous (metabolism, pathology)
  • Adult
  • Aged
  • Carcinoma, Ductal, Breast (metabolism, pathology)
  • Carcinoma, Papillary (metabolism, pathology)
  • Carrier Proteins (analysis, biosynthesis)
  • Cystadenoma, Serous (metabolism, pathology)
  • DNA Primers (chemistry)
  • Female
  • Humans
  • Immunohistochemistry
  • Intracellular Signaling Peptides and Proteins
  • Latent TGF-beta Binding Proteins
  • Male
  • Middle Aged
  • Pancreas (chemistry, metabolism)
  • Pancreatic Neoplasms (metabolism, pathology)
  • Peptide Fragments
  • Protein Biosynthesis
  • Protein Precursors
  • Proteins (analysis)
  • RNA, Messenger (analysis, biosynthesis)
  • RNA, Neoplasm (chemistry)
  • Transforming Growth Factor beta (analysis, biosynthesis)
  • Transforming Growth Factor beta1

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: